E. Emir, -. James, S. Meakin, S. Green, C. Scott et al., Hospitalisations dues aux effets indésirables des médicaments : résultats d'une étude nationale [cité 23 nov 2016] Disponible sur: http://social-­? sante.gouv.fr Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ. 3 juill, vol.329, issue.7456, pp.15-24, 2004.

A. and C. Clés, Disponible sur: http://www.atih.sante.fr/sites Analysis of adverse drug reactions for preventability, 2015.

B. Charpiat, B. Allenet, R. Roubille, L. Escofier, P. Bedouch et al., Facteurs à prendre en considération pour la gestion des interactions médicamenteuses en pratique clinique. Presse Médicale654?64. 8. FDA, Drug Development and Drug Interactions, www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIntera ctionsLabeling/ucm080499.htm 9. Guideline on the investigation of drug interactions -­? [cité 24 nov 2016]. Disponible sur, 2008.
DOI : 10.1016/j.lpm.2007.08.012

L. Benet, Changes in plasma protein binding have little clinical relevance, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.115-136, 2002.
DOI : 10.1067/mcp.2002.121829

J. Heuberger, S. Schmidt, and H. Derendorf, When is Protein Binding Important?*, Journal of Pharmaceutical Sciences, vol.102, issue.9, pp.3458-67, 2013.
DOI : 10.1002/jps.23559

W. Evans and M. Relling, Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics, Science, vol.286, issue.5439, pp.487-91, 1999.
DOI : 10.1126/science.286.5439.487

D. Allorge, la pharmacogénétique ou la promesse d'une médecine personnalisée, Ann Biol Clin, vol.62, pp.499-511, 2004.

J. Lin and A. Lu, Inhibition and Induction of Cytochrome P450 and the Clinical Implications, Clinical Pharmacokinetics, vol.35, issue.5, pp.361-90, 1998.
DOI : 10.2165/00003088-199835050-00003

D. Marin, A. Bazeos, F. Mahon, L. Eliasson, D. Milojkovic et al., Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib, Journal of Clinical Oncology, vol.28, issue.14, pp.2381-2389, 2010.
DOI : 10.1200/JCO.2009.26.3087

S. Karas, The potential for drug interactions, Annals of Emergency Medicine, vol.10, issue.12, pp.627-630, 1981.
DOI : 10.1016/S0196-0644(81)80085-6

P. Blower, R. De-wit, S. Goodin, and M. Aapro, Drug???drug interactions in oncology: Why are they important and can they be minimized?, Critical Reviews in Oncology/Hematology, vol.55, issue.2, pp.117-159, 2005.
DOI : 10.1016/j.critrevonc.2005.03.007

U. Werneke, J. Earl, C. Seydel, O. Horn, P. Crichton et al., Potential health risks of complementary alternative medicines in cancer patients, British Journal of Cancer, vol.90, issue.2, pp.408-421, 2004.
DOI : 10.1038/sj.bjc.6601560

R. Riechelmann, D. Giglio, and A. , Drug interactions in oncology: how common are they?, Annals of Oncology, vol.20, issue.12, 2009.
DOI : 10.1093/annonc/mdp369

V. Miranda, A. Fede, M. Nobuo, V. Ayres, A. Giglio et al., Adverse Drug Reactions and Drug Interactions as Causes of Hospital Admission in Oncology, Journal of Pain and Symptom Management, vol.42, issue.3, pp.342-53, 2011.
DOI : 10.1016/j.jpainsymman.2010.11.014

R. Van-leeuwen, T. Van-gelder, R. Mathijssen, and F. Jansman, Drug???drug interactions with tyrosine-kinase inhibitors: a clinical perspective, The Lancet Oncology, vol.15, issue.8, pp.315-326, 2014.
DOI : 10.1016/S1470-2045(13)70579-5

J. Shao, J. Markowitz, D. Bei, and A. G. , Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors, Journal of Pharmaceutical Sciences, vol.103, issue.12, pp.3810-3843, 2014.
DOI : 10.1002/jps.24113

S. Liewer and A. Huddleston, Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients, Expert Review of Anticancer Therapy, vol.15, issue.4, pp.453-64, 2015.
DOI : 10.1586/14737140.2015.1014807

I. Récoché, V. Rousseau, R. Bourrel, M. Lapeyre-­?mestre, L. Chebane et al., Drug? drug interactions with imatinib: An observational study, ) [Internet]. oct 2016, 2016.

N. Widmer, C. Bardin, E. Chatelut, A. Paci, J. Beijnen et al., Review of therapeutic drug monitoring of anticancer drugs part two ??? Targeted therapies, European Journal of Cancer, vol.50, issue.12, pp.2020-2056, 2014.
DOI : 10.1016/j.ejca.2014.04.015

S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint et al., Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, vol.109, issue.8, pp.3496-3505, 2007.
DOI : 10.1182/blood-2006-07-036012

J. Woyach, A. Johnson, and J. Byrd, The B-cell receptor signaling pathway as a therapeutic target in CLL, Blood, vol.120, issue.6, pp.1175-84, 2012.
DOI : 10.1182/blood-2012-02-362624

R. Davis, V. Ngo, G. Lenz, P. Tolar, R. Young et al., Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, vol.14, issue.7277, pp.88-92, 2010.
DOI : 10.1038/nature08638

S. Herman, A. Gordon, E. Hertlein, A. Ramanunni, X. Zhang et al., Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765, Blood, vol.117, issue.23, pp.6287-96, 2011.
DOI : 10.1182/blood-2011-01-328484

K. Okkenhaug and B. Vanhaesebroeck, PI3K in lymphocyte development, differentiation and activation, Nature Reviews Immunology, vol.3, issue.4, pp.317-347, 2003.
DOI : 10.1038/nri1056

L. Honigberg, A. Smith, M. Sirisawad, E. Verner, D. Loury et al., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proceedings of the National Academy of Sciences, vol.107, issue.29, pp.13075-80, 2010.
DOI : 10.1073/pnas.1004594107

J. Hoellenriegel, S. Meadows, M. Sivina, W. Wierda, H. Kantarjian et al., The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia, Blood, vol.118, issue.13, pp.3603-3615, 2011.
DOI : 10.1182/blood-2011-05-352492

Q. Yang, P. Modi, T. Newcomb, C. Queva, and V. Gandhi, Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma, Clinical Cancer Research, vol.21, issue.7, pp.1537-1579, 2015.
DOI : 10.1158/1078-0432.CCR-14-2034

E. Matutes, R. Morilla, K. Owusu-­?ankomah, A. Houlihan, and D. Catovsky, The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-­?cell disorders, Blood, vol.83, issue.6, pp.1558-1562, 1994.

A. Guide and ]. Internet, Disponible sur: http://www.has-­? sante, pp.2011-2020, 2016.

T. Zenz, A. Kröber, K. Scherer, S. Häbe, A. Bühler et al., Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up, Blood, vol.112, issue.8, pp.3322-3329, 2008.
DOI : 10.1182/blood-2008-04-154070

H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber et al., Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.26, pp.1910-1916, 2000.
DOI : 10.1056/NEJM200012283432602

R. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, vol.94, issue.6, pp.1840-1847, 1999.

J. L. Binet, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis, Cancer, vol.42, issue.1, pp.198-206, 1981.
DOI : 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V

A. Guide and ]. Internet, Disponible sur: http://www.has-­? sante.fr/portail/upload/docs/application, 2016.

F. Bertoni and M. Ponzoni, The cellular origin of mantle cell lymphoma, The International Journal of Biochemistry & Cell Biology, vol.39, issue.10, pp.1747-53, 2007.
DOI : 10.1016/j.biocel.2007.04.026

M. Dreyling and N. Md, Mantle Cell Lymphoma: Biology, Clinical Presentation, and Therapeutic Approaches, American Society of Clinical Oncology Educational Book, vol.34
DOI : 10.14694/EdBook_AM.2014.34.191

M. Gertz, Waldenstr??m macroglobulinemia: 2015 update on diagnosis, risk stratification, and management, American Journal of Hematology, vol.71, issue.2, pp.346-54, 2015.
DOI : 10.1002/ajh.23922

M. Dimopoulos, E. Kastritis, and I. Ghobrial, Waldenstr??m's macroglobulinemia: a clinical perspective in the era of novel therapeutics, Annals of Oncology, vol.27, issue.2, pp.233-273, 2016.
DOI : 10.1093/annonc/mdv572

F. Cameron and M. Sanford, Ibrutinib: First Global Approval, Drugs, vol.31, issue.1, pp.263-71, 2014.
DOI : 10.1007/s40265-014-0178-8

S. Ramanathan, J. F. Sharma, S. Kearney, and B. , Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib, Clinical Pharmacokinetics, vol.97, issue.10, pp.33-45, 2016.
DOI : 10.1007/s40262-015-0304-0

F. Jin, Y. Gao, H. Zhou, L. Fang, X. Li et al., Population pharmacokinetic modeling of idelalisib, a novel PI3K?? inhibitor, in healthy subjects and patients with hematologic malignancies, Cancer Chemotherapy and Pharmacology, vol.37, issue.6, pp.89-98, 2016.
DOI : 10.1007/s00280-015-2891-8

J. De-jong, J. Sukbuntherng, D. Skee, J. Murphy, O. Brien et al., The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia, Cancer Chemotherapy and Pharmacology, vol.75, issue.5, pp.907-923, 2015.
DOI : 10.1007/s00280-015-2708-9

C. Matheny, M. Lamb, K. Brouwer, and G. Pollack, Pharmacokinetic and Pharmacodynamic Implications of P-glycoprotein Modulation, Pharmacotherapy, vol.58, issue.7, pp.778-796, 2001.
DOI : 10.1046/j.1432-1327.1999.00644.x

K. Fenner, M. Troutman, S. Kempshall, J. Cook, J. Ware et al., Drug???Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro???In Vivo Correlation Using Digoxin as a Probe Drug, Clinical Pharmacology & Therapeutics, vol.38, issue.2, pp.173-81, 2009.
DOI : 10.1177/0091270006292624

E. Garattini and M. Terao, The role of aldehyde oxidase in drug metabolism, Expert Opinion on Drug Metabolism & Toxicology, vol.6, issue.4, pp.487-503, 2012.
DOI : 10.1371/journal.pone.0005348

R. Obach, P. Huynh, M. Allen, and C. Beedham, Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs, The Journal of Clinical Pharmacology, vol.185, issue.Suppl., pp.7-19, 2004.
DOI : 10.1177/0091270003260336

D. Pryde, D. Dalvie, Q. Hu, P. Jones, R. Obach et al., Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery, Journal of Medicinal Chemistry, vol.53, issue.24, pp.8441-60, 2010.
DOI : 10.1021/jm100888d

S. Lee, J. Park, D. Kim, S. Bae, Y. Chin et al., In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug???drug interactions, Toxicology Letters, vol.232, issue.2, pp.458-65, 2015.
DOI : 10.1016/j.toxlet.2014.11.018

T. Kiang, M. Ensom, and T. Chang, UDP-glucuronosyltransferases and clinical drug-drug interactions, Pharmacology & Therapeutics, vol.106, issue.1, pp.97-132, 2005.
DOI : 10.1016/j.pharmthera.2004.10.013

J. Byrd, J. Brown, O. Brien, S. Barrientos, J. Kay et al., Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, New England Journal of Medicine, vol.371, issue.3, pp.213-236, 2014.
DOI : 10.1056/NEJMoa1400376

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134521

R. Furman, J. Sharman, S. Coutre, B. Cheson, J. Pagel et al., Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.370, issue.11, pp.997-1007, 2014.
DOI : 10.1056/NEJMoa1315226

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365

A. Gopal, B. Kahl, S. De-vos, N. Wagner-­?johnston, S. Schuster et al., PI3K?? Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma, New England Journal of Medicine, vol.370, issue.11, pp.1008-1026, 2014.
DOI : 10.1056/NEJMoa1314583

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039496

M. Levade, E. David, C. Garcia, P. Laurent, S. Cadot et al., Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions, Blood, vol.124, issue.26, pp.3991-3996, 2014.
DOI : 10.1182/blood-2014-06-583294

A. Mato, C. Nabhan, P. Barr, C. Ujjani, B. Hill et al., Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience, Blood, vol.128, issue.18, p.2016, 2016.
DOI : 10.1182/blood-2016-05-716977

J. De-jong, D. Skee, J. Murphy, J. Sukbuntherng, P. Hellemans et al., Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants, Pharmacology Research & Perspectives, vol.43, issue.4, p.156, 2015.
DOI : 10.1002/prp2.156

L. Kuhn, E. Levêque, D. Lioure, B. Gourieux, B. Bilbault et al., Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report, Journal of Clinical Pharmacy and Therapeutics, vol.34, issue.1, pp.104-109, 2016.
DOI : 10.1111/jcpt.12355

L. De-zwart, J. Snoeys, D. Jong, J. Sukbuntherng, J. Mannaert et al., Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling, Clinical Pharmacology & Therapeutics, vol.34, issue.5, pp.548-57, 2016.
DOI : 10.1002/cpt.419

J. Bossaer and K. Chakraborty, Drug interaction between idelalisib and diazepam resulting in altered mental status and respiratory failure, Journal of Oncology Pharmacy Practice, vol.41
DOI : 10.1177/1078155216653705

J. Byrd, R. Furman, S. Coutre, I. Flinn, J. Burger et al., Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.369, issue.1, pp.32-42, 2013.
DOI : 10.1056/NEJMoa1215637

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772525

M. Wang, S. Rule, P. Martin, A. Goy, R. Auer et al., Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma, New England Journal of Medicine, vol.369, issue.6, pp.507-523, 2013.
DOI : 10.1056/NEJMoa1306220

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513941

S. Treon, C. Tripsas, K. Meid, D. Warren, G. Varma et al., Ibrutinib in Previously Treated Waldenstr??m???s Macroglobulinemia, New England Journal of Medicine, vol.372, issue.15, pp.1430-1470, 2015.
DOI : 10.1056/NEJMoa1501548

G. Compaci, L. Ysebaert, L. Obéric, H. Derumeaux, and G. Laurent, Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience, International Journal of Nursing Studies, vol.48, issue.8, pp.926-958, 2011.
DOI : 10.1016/j.ijnurstu.2011.01.008

. Interactions-médicamenteuses-­? and . Ansm, Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cité 26 nov 2016]. Disponible sur: http://ansm.sante.fr/Dossiers/Interactions-­?medicamenteuses/Interactions-­? medicamenteuses

I. Cascorbi, Drug Interactions?Principles, Examples and Clinical Consequences, Dtsch Ärztebl Int. août, vol.109, issue.33?34, pp.546-56, 2012.

E. Wu, A. Guerin, A. Yu, V. Bollu, A. Guo et al., Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia, Current Medical Research and Opinion, vol.26, issue.12, pp.2861-2870, 2010.
DOI : 10.1185/03007995.2010.533648

T. Darkow, H. Henk, S. Thomas, W. Feng, J. Baladi et al., Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs, PharmacoEconomics, vol.52, issue.5
DOI : 10.2165/00019053-200725060-00004

P. Ganesan, T. Sagar, B. Dubashi, R. Rajendranath, K. Kannan et al., Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia, American Journal of Hematology, vol.94, issue.6, pp.471-475, 2011.
DOI : 10.1002/ajh.22019